Preparation method and application of a PET imaging agent targeting TSPO receptor
By developing the 18F-TFQC, a targeted TSPO receptor PET imaging agent, 18F-TFQC, the problem of low specificity and insufficient signal-to-noise ratio in the prior art is solved, and effective identification and diagnosis of TSPO receptor inflammatory lesions is achieved. Important clinical application value.
Patent Information
- Application Number
- CN202211397576.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-11-09
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2042-11-09
AI Technical Summary
The existing targeted TSPO receptor imaging agents have problems such as low specificity, insufficient signal-to-noise ratio and polymorphism dependence of TSPO genes, which makes it difficult to distinguish the specific binding of imaging agents in some patients, limiting them. Clinical application.
Developed an 18F-TFQC, a 18F-labeled targeted TSPO receptor PET imaging agent, which can be quickly excreted from the body through Br-CF2 through high radioactive chemical purity, good biostability and short in vivo aggregation time. -QC precursor compounds are labeled with radionuclide F-18, providing better specificity and signal-to-noise ratio.
18F-TFQC imaging agent can effectively identify inflammatory lesions targeting TSPO receptors, have good blood-brain barrier penetration effect, and have important clinical value in inflammation diagnosis, prediction and efficacy monitoring.
Smart Images

Figure CN115611819B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a preparation method and application of a PET imaging agent targeting TSPO receptors, belonging to the technical field of radiopharmaceutical chemistry. Background Art
[0002] Positron emission computerized tomography (PET), as an important means of medical imaging, can reflect the disease conditions at the cellular and molecular levels. 18 F-FDG PET has been successfully used in oncology, neurology, and cardiovascular medicine. 18 As a nonspecific imaging agent, F-FDG often produces false positive results in inflammation imaging. In addition, higher levels of 18 Accumulation of F-FDG imaging agent makes it difficult to detect inflammatory lesions near these organs or tissues, affecting the sensitivity and specificity of detection. Macrophages, a key component of innate immunity, can activate into either M1 or M2 macrophages in local inflammatory environments. M1 macrophages promote inflammation and inhibit cell proliferation, while M2 macrophages exert anti-inflammatory effects, promote cell proliferation, and promote tissue repair. In recent years, numerous studies have demonstrated that activated macrophages are closely associated with the development and progression of certain cardiovascular diseases, neurological diseases, autoimmune diseases, and tumors. Therefore, targeted imaging of activated macrophages could aid in the early diagnosis and targeted treatment of a variety of diseases.
[0003] The translocator protein (TSPO), also known as the peripheral benzodiazepine receptor (PBR), with a relative molecular mass of 18kD, is mainly distributed in the outer membrane of mitochondria and is highly expressed in macrophages, monocytes, activated microglia and astrocytes.
[0004] TSPO imaging agents can be used to study a variety of diseases. In the field of neurological diseases, Colasanti et al. conducted a study on 11 multiple sclerosis (MS) patients and 11 normal subjects. 11 C-PBR111 PET scan revealed 11 The uptake of C-PBR111 in the white matter lesions of MS patients is higher than that in normal people, and the uptake of imaging agent in the lesions is positively correlated with the severity of MS, indicating that 11 C-PBR111 PET imaging can quantitatively assess the inflammation of the white matter in MS patients and guide clinical medication. 11C-vinpocetine PET observed the changes in TSPO in the brains of 9 stroke patients and found that one week after the stroke, the radioactive uptake in the ischemic core and the peri-infarct area increased, and as the time after the stroke prolonged, the radioactive uptake in the above areas steadily decreased, indicating that the activation of microglia after stroke is time-dependent. 11 C-vinpocetine PET has the potential to observe the areas of microglial activation and assess the severity of stroke in stroke patients.
[0005] James et al. found that 18 F-GE180 PET evaluated the effect of LM11A-31, a drug for the treatment of Alzheimer's disease (AD), on the activation of microglia in AD model mice. 18 F-GE180 has a certain sensitivity in monitoring neuroinflammation and evaluating microglial activation in AD mice. Zinnhardt et al. used a mouse glioma model to demonstrate that 18 F-DPA-714 PET / CT can reflect the inflammatory microenvironment of glioma at different stages and provide information for clinical diagnosis and treatment. However, since TSPO imaging cannot distinguish the expression of tumor cells from inflammatory cells around the tumor, its clinical application in brain tumors is limited. In terms of peripheral inflammatory diseases, Gaemperli et al. studied 9 patients with symptomatic and 27 asymptomatic carotid artery stenosis. 11 C-PK11195 PET / CT scan, confirmed by immunofluorescence pathology results 11 C-PK11195 PET / CT can distinguish symptomatic from asymptomatic atherosclerotic plaques by imaging activated macrophages. Hatori et al. and Xie et al. also confirmed this by establishing corresponding disease mouse models. 18 F-FEDAC PET / CT can be used for dynamic monitoring of liver fibrosis and quantitative detection and staging of non-alcoholic fatty liver disease.
[0006] First generation TSPO imaging agents 11 The synthesis of C-PK11195 has made TSPO-targeted positron emission tomography imaging agents a surrogate marker of microglial activation. 11 The C-PK11195 imaging agent has been used in preclinical and clinical studies of various neuroinflammatory diseases. 11 C-PK11195 has low brain penetration, high nonspecificity and 11 C has a shorter half-life, 18 F-FEDAA1106, 18 F-PBR28, 18Second-generation TSPO-specific imaging agents, represented by F-DPA714, emerged as a response to this challenge. While these second-generation TSPO imaging agents offer improved receptor specificity and image signal-to-noise ratio, a polymorphism in exon 4 of the TSPO gene (rs6971) results in an alanine-to-threonine substitution (A147T), resulting in three binding types for TSPO: high-affinity (Ala / Ala), mixed-affinity (Ala / Thr), and low-affinity (Thr / Thr). These differences in binding between different imaging agents for different TSPO types complicate quantitative analysis and image comparison using these second-generation TSPO imaging agents. Furthermore, studies have found that specific binding with some second-generation TSPO imaging agents is difficult to distinguish from nonspecific binding in patients with Thr / Thr TSPO, thus limiting their clinical application.
[0007] 11 As a third-generation imaging agent, C-ER176 has better specificity and signal-to-noise ratio than first- and second-generation imaging agents, and no significant dependence on the rs6971 polymorphism has been observed. It can better reflect TSPO expression and microglial activation, so its clinical application value urgently needs extensive experimental verification. However, C-11 has a short half-life of 20.3 minutes. If F-18, which has a longer half-life (110 minutes), can be used instead of C-11 for radiolabeling without affecting the properties of the drug, it would be of great significance for its clinical application. Summary of the Invention
[0008] The purpose of the present invention is to propose and prepare a TSPO receptor targeting imaging agent to solve the problems and defects of the existing imaging agents. 18 F-labeled PET imaging agent targeting TSPO receptor 18 F-TFQC has high radiochemical purity, good biological stability, a sufficiently long half-life, a short accumulation time in the body, can be quickly excreted from the body, and can effectively identify inflammatory lesions targeting TSPO receptors.
[0009] In order to achieve the above object, the present invention discloses a PET imaging agent targeting TSPO receptor 18 F-TFQC, the PET imaging agent 18 The radiochemical purity of F-TFQC is >99%, and its chemical structure is:
[0010]
[0011] Preferably, the PET imaging agent 18 F-TFQC is obtained by labeling the precursor compound Br-CF2-QC with radionuclide F-18 as shown below:
[0012]
[0013] The present invention also provides a method for synthesizing the PET imaging agent according to claim 1. 18 The precursor compound of F-TFQC, Br-CF2-QC, has the chemical structure:
[0014]
[0015] The present invention also provides a method for preparing the above-mentioned precursor compound Br-CF2-QC, which is prepared by the following chemical synthesis route:
[0016]
[0017] The present invention also provides the above-mentioned PET imaging agent targeting TSPO receptor 18 The application of F-TFQC in the preparation of diagnostic reagents or kits for inflammation can be used for PET / CT or PET / MR imaging.
[0018] Preferably, the present invention comprises a diagnostic reagent or kit for preparing brain neuroinflammation.
[0019] Compared with the prior art, the present invention has the following beneficial effects:
[0020] (1) The present invention synthesizes the first precursor compound Br-CF2-QC by labeling it with radioactive nuclide F-18. 18 F-TFQC, 18 The radiochemical purity of F-TFQC is greater than 99%. The preparation method of the present invention is simple and rapid, and the radiochemical yield of the preparation method is approximately (11.90±1.40)% (after attenuation correction).
[0021] (2) Furthermore, the present invention also designs a chemical synthesis route for the precursor compound Br-CF2-QC, which is simple, fast and easy to purify;
[0022] (3) Positron imaging agent of the present invention 18 F-TFQC can be used as a PET imaging probe targeting inflammation because of its good effect of penetrating the blood-brain barrier. 18 F-TFQC is expected to become a candidate PET imaging probe for brain neuroinflammation. 18 F-TFQC imaging agents have important clinical value in the diagnosis and screening of inflammation, prediction of prognosis and monitoring of therapeutic efficacy targeting TSPO receptors. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 The PET probe of the present invention 18Chemical structure of F-TFQC;
[0024] Figure 2 PET probe 18 Biodistribution diagram of F-TFQC in various organs and tissues of normal mice;
[0025] Figure 3 PET probe 18 In vivo imaging of F-TFQC in rats. DETAILED DESCRIPTION
[0026] To make the present invention more clearly understood, preferred embodiments are described in detail below with reference to the accompanying drawings.
[0027] Example 1
[0028] Synthesis of precursor Br-CF2-QC:
[0029]
[0030] Step 1: Under N2 protection, anthranilic acid (13.714 g, 100 mmol) and anhydrous THF (160 mL) were added to a 500 mL three-necked flask. The mixture was cooled to 0°C and N,N'-carbonyldiimidazole (16.215 g, 100 mmol) was added. The reaction mixture was returned to room temperature and stirred for 2 h. Dimethylhydroxylamine hydrochloride (97.54 g, 100 mmol), triethylamine (10.12 g, 100 mmol), and THF (80 mL) were added and allowed to react overnight. LC-MS confirmed the complete reaction of the starting material. H2O (200 mL) was added to the reaction mixture and extracted three times with EA (150 mL × 3). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (PE:EA = 1:1) to obtain the product Pre-CF3-1 (14.4 g) in an 80% yield.
[0031] Step 2: Under N2 protection, m-bromotoluene (13.3 g, 77.7 mmol) and THF (100 mL) were added to a 500 mL three-necked flask. The mixture was cooled to -78°C and n-butyllithium (77.7 mL, 155.4 mmol) was slowly added dropwise. The mixture was stirred at this temperature for 1 h. Pre-CF3-1 (14.0 g, 77.7 mmol) and a THF solution (100 mL) were then slowly added dropwise at -78°C over approximately 30 min. The mixture was returned to room temperature and stirred overnight. LC-MS confirmed the complete reaction. Saturated ammonium chloride solution was added and the mixture was extracted three times with EA (150 mL x 3). The organic phase was collected, dried, concentrated, and purified by column chromatography (PE:EA = 50:1) to afford 7.3 g of Pre-CF3-2 in a 44.5% yield.
[0032] Step 3: To a 250 mL reaction flask, add Pre-CF3-2, ethyl glyoxylate, ammonium acetate, anhydrous ethanol, and H2O in sequence. Stir at room temperature for 72 h. LC-MS analysis confirmed the complete reaction of most of the starting materials. Concentrate the anhydrous ethanol and extract three times with EA (50 mL x 3). The organic phase was collected, dried, concentrated, and purified by column chromatography (PE:EA = 5:95) to obtain 3.6 g of Pre-CF3-3 (37.5% yield).
[0033] Step 4: To a 100 mL three-necked flask, add Pre-CF3-3 (3.5 g, 12.0 mmol), NaOH (0.96 g, 24.0 mmol), and anhydrous ethanol (40 mL). Stir at room temperature overnight. TLC confirms the complete reaction of the starting material. Concentrate to remove the ethanol, add hydrochloric acid (1 N, 20 mL), adjust the pH to 1, and extract three times with EA (40 mL x 3). Collect the organic phase and concentrate to dryness under reduced pressure to obtain 2.5 g of Pre-CF3-4 (yield: 80.5%).
[0034] Step 5: Under N2 protection, Pre-CF3-4 (2.3 g, 8.7 mmol) was added to a 100 mL three-necked flask in sequence, followed by oxalyl chloride (2.2 g, 17.4 mmol) and DCM (25 mL). A small amount of DMF was added dropwise, and the mixture was stirred at room temperature overnight. The reaction was complete after TLC. The mixture was concentrated to dryness and then dried with an oil pump to obtain a crude product of Pre-CF3-5: 1.82 g, with a yield of 74.2%.
[0035] Step 6: Under N2 protection, to a 100 mL three-necked flask were added Pre-CF3-5 (1.8 g, 6.4 mmol), followed by N-methyl-2-butylamine (0.47 g, 6.4 mmol), triethylamine (1.94 g, 19.2 mmol), and DCM (20 mL). Stirring was continued at room temperature for 2 h. TLC monitored the reaction for complete reaction. Column chromatography afforded 1.75 g of Pre-CF3-6 in an 85.6% yield.
[0036] Step 7: Under N2 protection, to a 100 mL three-necked flask, add Pre-CF3-6 (1.7 g, 5.3 mmol) and then THF (20 mL). Cool to 0°C, add KOtBu (1.8 g, 15.9 mmol), maintain stirring at 0°C for 1 h, and slowly add CH3I (0.91 g, 6.4 mmol). After addition, return to room temperature and stir for 16 h. LC monitors the reaction for complete reaction. The reaction solution is poured into saturated ammonium chloride solution (25 mL) and extracted three times with EA (25 mL x 3). The organic phase is collected and purified by column chromatography to obtain 1.14 g of the product, with a yield of 64.5%.
[0037] Step 8: Under N2 protection, to a 50 mL three-necked flask were added Pre-CF3-7 (1.1 g, 3.3 mmol), NBS (0.71 g, 3.9 mmol), AIBN (0.16 g, 0.99 mmol), and DCE (15 mL). The temperature was raised to 80°C and the reaction was carried out for 16 h. LC-MS analysis indicated the formation of the product. The product was concentrated to dryness without post-treatment and used in the next step. The product Pre-CF3-8 was obtained: 0.72 g, yield: 53.2%.
[0038] Step 9: Under N2 protection, Pre-CF3-8 (0.7 g, 1.7 mmol), sodium trifluoromethanesulfinate (0.27 g, 1.7 mmol) and ACN (acetonitrile, 15 mL) were added in sequence to a 50 mL three-necked flask, and the temperature was raised to 80°C. The reaction was allowed to proceed for 16 h. LC-MS detection showed that the reaction of the raw materials was complete. The mixture was cooled to room temperature, concentrated, and subjected to column chromatography with PE:EA=2:1 to obtain the product Pre-CF3-9: 0.67 g, with a yield of 85.3%.
[0039] Step 10: Under N2 protection, Pre-CF3-9 (0.6 g, 1.3 mmol), NFSI (N-fluorobisbenzenesulfonamide, 0.83 g, 2.65 mmol), K3PO4 (0.83 g, 3.9 mmol) and DMF (15 mL) were added in sequence to a 50 mL three-necked flask. The reaction was stirred at room temperature for 16 h. LC-MS detection showed that the reaction of the raw materials was complete. Saturated ammonium chloride solution (15 mL) was added and stirred for 30 min. EA (20 mL×3) was added and extracted three times. Column chromatography was performed with PE:EA=2:1 to obtain the product Pre-CF2-QC: 0.23 g, yield: 35.4%.
[0040] Step 11: Under N2 protection, Pre-TFQC (Pre-CF2-QC), LiBr and MeCN were added sequentially to a 50 mL three-necked flask, heated to 80°C, and stirred for 16 hrs. LC-MS detection showed that the reaction of the raw material was complete. The product was concentrated, and EA and saturated brine were added. The mixture was separated and separated by column chromatography (Hex:EA=1:1) to obtain 140 mg of the precursor compound Br-CF2-QC.
[0041] Example 2
[0042] Target compound PET probe 18 Synthesis of F-TFQC:
[0043]
[0044] 18F- was produced by Sumitomo HM-20DE accelerator in Japan. The specific labeling experiment was carried out on Sumitomo F-18 multifunctional synthesis module (F18-multi-P). The specific steps included: using 10mL 1M K2CO3 and 60mL deionized water to activate the QMA column to capture the accelerator bombardment 18 F - Then, the QMA column was washed with a mixture of 20 mg TEAB dissolved in 0.5 mL deionized water and 0.5 mL acetonitrile. 18 F - The eluted product was transferred to a reaction flask and dried twice at 120°C and 100°C, respectively. 5 mg of the precursor Br-CF2-QC dissolved in 1 mL of anhydrous acetonitrile was then added to the reaction flask and reacted at 110°C for 20 min. After the reaction, the product was cooled to room temperature and separated by preparative radio-HPLC (column: Agilent C18, 5 μm, 9.4×250 mm; mobile phase: 6.0 / 4.0 acetonitrile / water (containing 0.1% TFA); flow rate: 3 mL / min). 18 F-TFQC. The activity of the final product is measured with an activity reagent and then corrected for decay until the reaction is complete. 18 The radiochemical yield of F-TFQC was approximately (11.90±1.40)% (after attenuation correction), and the radiochemical purity of the product was greater than 99% after quality control.
[0045] Application Example 1
[0046] PET probe of the present invention 18 In vitro stability experiment of F-TFQC:
[0047] The obtained in Example 2 18 Approximately 1 mCi of F-TFQC was placed in 100 μL of 0.9% saline, mixed thoroughly, and stored at 37°C. Samples were taken at 0.5, 1, 3, and 6 hours, and their purity was assessed using analytical HPLC. HPLC results showed that the purity of the PET probe after 6 hours was comparable to that immediately following labeling, demonstrating the high stability of the molecular probe with minimal degradation.
[0048] Application Example 2
[0049] PET probe of the present invention 18 Biodistribution experiment of F-TFQC:
[0050] The obtained in Example 2 18Approximately 100 μCi of F-TFQC was injected intravenously into 21 8-week-old male ICR mice. Three mice were sacrificed at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, and 4 hours. Tissues including blood, heart, liver, spleen, lung, kidney, stomach, small intestine, bone, muscle, and brain were collected, weighed, and radioactivity counted. After decay correction, the counts for each tissue sample were compared with the standard counts, and the results were expressed as %ID / g (the percentage of the injected dose per gram of tissue sample), which is the radioactivity of each organ. 18 Relative absorbance value of F-TFQC, biological distribution display 18 F-TFQC is rapidly distributed throughout the body through the blood circulation, mainly concentrated in the lungs, followed by the heart, spleen, and kidneys. Other tissues and organs accumulate less, and most of them can be excreted after 4 hours. Figure 2 shown.
[0051] Application Example 3
[0052] PET probe of the present invention 18 In vivo imaging assay of F-TFQC:
[0053] The obtained in Example 2 18 About 1 mCi of F-TFQC was injected into epilepsy model SD rats (experimental group) and normal SD rats (control group) through the tail vein.
[0054] The results are as follows Figure 3 As shown, no obvious imaging agent uptake was observed in the hippocampus of the normal SD rats (control group), while obvious imaging agent accumulation was observed in the right hippocampus of the epilepsy model SD rats (experimental group).
[0055] The imaging results show 18 F-TFQC, as a PET imaging agent targeting TSPO receptors, can effectively identify epileptic lesions.
[0056] The above embodiments are only preferred embodiments of the present invention and are not intended to limit the present invention in any form or substance. It should be noted that ordinary technicians in this technical field can make several improvements and supplements without departing from the present invention, and these improvements and supplements should also be regarded as the scope of protection of the present invention.
Claims
1. A PET imaging agent targeting TSPO receptors 18 The preparation method of F-TFQC is characterized in that: The PET imaging agent 18 The radiochemical purity of F-TFQC is >99%, and its chemical structure is: The PET imaging agent 18 F-TFQC is obtained by labeling the precursor compound Br-CF2-QC with radionuclide F-18 as shown below: The precursor compound Br-CF2-QC is prepared by the chemical synthesis route shown below: The PET imaging agent 18 The synthetic route of F-TFQC is as follows:
2. The method for preparing the precursor compound Br-CF2-QC according to claim 1, characterized in that: It is prepared by the chemical synthesis route shown below:
